Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Equity (2016 - 2025)

Historic Return on Equity for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 0.11%.

  • Protalix BioTherapeutics' Return on Equity rose 4200.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11%, marking a year-over-year increase of 4200.0%. This contributed to the annual value of 0.08% for FY2024, which is 3800.0% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Return on Equity is 0.11%, which was up 4200.0% from 0.13% recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Return on Equity peaked at 9.66% during Q4 2021, and registered a low of 10.46% during Q3 2021.
  • Moreover, its 5-year median value for Return on Equity was 0.14% (2023), whereas its average is 0.6%.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Return on Equity plummeted by -106700bps in 2021, and later surged by 121300bps in 2022.
  • Protalix BioTherapeutics' Return on Equity (Quarter) stood at 9.66% in 2021, then crashed by -87bps to 1.3% in 2022, then crashed by -89bps to 0.14% in 2023, then plummeted by -46bps to 0.08% in 2024, then soared by 37bps to 0.11% in 2025.
  • Its Return on Equity stands at 0.11% for Q3 2025, versus 0.13% for Q2 2025 and 0.09% for Q1 2025.